Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $22.9 million.

  • Karyopharm Therapeutics' Net Cash Flow rose 32127.17% to $22.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.3 million, marking a year-over-year increase of 9266.27%. This contributed to the annual value of -$1.9 million for FY2025, which is 12017.02% down from last year.
  • Per Karyopharm Therapeutics' latest filing, its Net Cash Flow stood at $22.9 million for Q4 2025, which was up 32127.17% from -$1.1 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Net Cash Flow ranged from a high of $63.7 million in Q4 2022 and a low of -$70.4 million during Q2 2022
  • Moreover, its 5-year median value for Net Cash Flow was -$3.1 million (2021), whereas its average is -$3.4 million.
  • In the last 5 years, Karyopharm Therapeutics' Net Cash Flow skyrocketed by 110779.96% in 2021 and then crashed by 445821.36% in 2022.
  • Karyopharm Therapeutics' Net Cash Flow (Quarter) stood at $57.1 million in 2021, then grew by 11.48% to $63.7 million in 2022, then tumbled by 86.62% to $8.5 million in 2023, then tumbled by 221.25% to -$10.3 million in 2024, then soared by 321.27% to $22.9 million in 2025.
  • Its Net Cash Flow was $22.9 million in Q4 2025, compared to -$1.1 million in Q3 2025 and -$412000.0 in Q2 2025.